Search Results

Novartis Files Localized Production Application in China for Lutetium [177Lu] Vipivotide Tetraxetan

On August 24, information on the website of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration showed that Novartis' nuclear medicine product Lutetium [177Lu] Vipivotide Tetraxetan had a localized production application submitted in China. On the same day, two indications for the drug were proposed for priority review, and the relevant review matters may correspond to this localized production application. Lutetium [177Lu] Vipivotide Tetraxetan, namely 177Lu-PSMA-617, is a radioligand therapy (RLT) drug acquired by Novartis following its acquisition of Endocyte. The drug consists of a small-molecule compound targeting prostate-specific membrane antigen (PSMA) conjugated to the therapeutic radionuclide Lutetium-177. Upon entering the bloodstream, the drug binds to prostate cancer cells expressing PSMA, and...

2026-08-25

Angolan Public Health and Medical Training Delegation Visits the Affiliated Hospital of Southwest Medical University, Focusing on Nuclear Medicine Diagnosis and Treatment Technologies

Recently, the "Angola Public Health and Medical Training Program," organized by the International Exchange Center of the Sichuan Provincial Health Commission, was held at the Affiliated Hospital of Southwest Medical University. An 18-member delegation comprising Angolan health administrators and medical personnel visited the hospital for exchange, with a focus on learning about the development and clinical application of nuclear medicine, urology, and other related disciplines. Jiang Yong, member of the Standing Committee of the Party Committee, Vice President of Southwest Medical University, and President of the Affiliated Hospital, welcomed the Angolan delegation and introduced the hospital's basic information. He stated that under the guidance of the Sichuan Provincial Health Commission, the hospital will leverage its disciplinary advantages as a university-affiliated hospital and a Sichuan Provincial Medical Center to carry out practical cooperation with Angola in talent cultivation, technical exchange, and hospital management.

2026-08-25

Russia and Algeria Advance Cooperation in Peaceful Uses of Nuclear Energy

August 22 news, Russian Ambassador to Algeria Alexey Solomatin said in an interview that Russia and Algeria are advancing cooperation in the field of peaceful uses of nuclear energy, with direct working contacts established between the relevant agencies of the two countries. Solomatin stated that cooperation between the two countries in this field is expanding. The basis for bilateral cooperation is the Intergovernmental Agreement on Cooperation in the Peaceful Uses of Nuclear Energy signed in 2014. In addition, Russia and Algeria signed the Roadmap for Cooperation in the Peaceful Uses of Nuclear Energy during the 2024 International Atomic Energy Expo (Atomexpo), outlining the main directions of bilateral cooperation. He noted that the practical implementation of the agreements will begin in 2...

2026-08-25

Russian Far Eastern Federal University Develops Ultrafast Ceramic Scintillators for Rapid Ionizing Radiation Detection

On August 21, 2026, scientists at the Russian Far Eastern Federal University, with support from the Russian Science Foundation, are developing ceramic materials for ultrafast detection of ionizing radiation. The results could be used in the future for medical diagnostics, baggage and cargo security screening, radiation monitoring, and scientific equipment requiring fast, precise radiation detection. The project, titled "Ultrafast Ceramic Scintillators for Ionizing Radiation Detection," is led by Anastasia Vonovskikh, a researcher at the Research and Education Center for Advanced Ceramic Materials, Department of Industrial Safety, Polytechnic Institute, Far Eastern Federal University. Scintillators are a class of materials that emit light when exposed to ionizing radiation. Detectors record these light signals to determine radiation intensity and energy. Currently, most related equipment uses single-crystal scintillators, but their production typically requires significant energy and resource inputs. The Far Eastern Federal University team proposes special ceramic materials as an alternative, aiming to improve detection speed and efficiency, making them more suitable for detecting trace amounts of radiation.

2026-08-25

Beijing Nuclear Industry Hospital and Aviation General Hospital Hold Nursing Academic Exchange Focusing on Nuclear Medicine Specialty Nursing and Continuous Home-Based Care

On August 21, Beijing Nuclear Industry Hospital, in collaboration with Aviation General Hospital, held a nursing academic exchange meeting. Nursing management teams, nursing backbone staff and related professionals from both hospitals attended the meeting, engaging in exchanges on humanistic nursing development, the "Internet+" continuous home-based care service model, and nuclear medicine specialty nursing, exploring practical pathways for high-quality development of nursing services. Jin Congjun, Vice President of Beijing Nuclear Industry Hospital, introduced the hospital's development overview in his speech and welcomed the visiting nursing expert team from Aviation General Hospital. He expressed his hope to leverage this exchange as an opportunity to establish a regular learning platform, promote mutual learning and complementarity between the two sides, and jointly enhance nursing service capabilities. Aviation General...

2026-08-25

Phase I of Jinjiang Ruisi Ke Particle Therapy Equipment Production Base Fully Operational

Recently, Phase I of the Ruisi Ke Advanced Particle Therapy Equipment Production Base for tumors, located in Dongshi Town, Jinjiang, Fujian, has been fully put into operation, marking new progress in the life and health industry sector of Quanzhou South Wing National High-Tech Zone. As the first launch project in the local effort to build the "China Nuclear Medicine Valley," this project is accelerating the clustering of the nuclear medical equipment industry chain. It is understood that all four production workshops of Phase I of the Ruisi Ke production base have commenced operations, with a total floor area of nearly 30,000 square meters. Inside the workshops, relevant personnel are performing precision machining on core components of the proton therapy system. The base possesses research and development, production, and testing capabilities for proton therapy systems and boron neutron capture therapy systems, making it one of the few...

2026-08-24

Hitachi Receives Order for Heavy Ion Therapy System from Shanghai Proton and Heavy Ion Center

Recently, Hitachi (China) Co., Ltd. received an order for one heavy ion cancer therapy system from the Shanghai Proton and Heavy Ion Center, and the two parties held a signing ceremony. This order is part of the Phase II construction project of the Shanghai Proton and Heavy Ion Center. Rendering of the completed Phase II project of the Shanghai Proton and Heavy Ion Center The Shanghai Proton and Heavy Ion Center is the first medical institution in China to possess both proton and heavy ion radiotherapy technologies. To further meet the demand for precision medicine, the center launched its Phase II construction in 2025, planning to add particle therapy system equipment. According to the project arrangement, the heavy ion therapy system ordered this time will be equipped with 4 treatment rooms and integrate Hitachi's moving-target tracking technology and pencil-beam scanning irradiation technology.

2026-08-24

South Korea Clarifies Statutory Functions of KAERI Radiation Injury Treatment Hospital

The Korea Atomic Energy Research Institute (KAERI) announced on August 24 that the National Assembly had passed a partial amendment to the Act on the Promotion of Radiation and Radioisotope Utilization at its plenary session on August 20, incorporating the functions of a radiation injury treatment hospital, along with supporting research and technology development, into the institute's statutory scope of business. Under the amendment, relevant institutions will provide specialized medical services to individuals who have sustained radiation injuries or are at risk of such injuries. Radiation injury generally refers to health abnormalities in the human body resulting from excessive exposure to radiation. Such injuries may not manifest immediately after exposure; even when early symptoms appear only as skin redness, they can later progress to ulceration, necrosis, and affect the blood or bone marrow systems. Some individuals also require long-term follow-up to monitor for delayed health risks such as cancer.

2026-08-24

Iran Says Its Atomic Energy Organization's Medical Products Serve Over 1.5 Million Patients Annually

Mohammad Eslami, head of the Atomic Energy Organization of Iran, recently stated that more than 1.5 million patients in Iran use diagnostic and therapeutic products developed by the organization each year, and related medical products have also been exported to multiple countries. Eslami made these remarks at a ceremony held by Iran's nuclear industry to celebrate Physicians' Day. He said that promoting the application of advanced treatment methods is one of the key directions of Iran's scientific and technological development. The progress made by Iranian researchers in cold plasma technology has opened up a "brand-new and promising path" for medical applications. He stated that plasma technology has not only achieved notable results in the research field but has also played a role in healthcare settings.

2026-08-24

Radexel leads South Korea's KRW 35.2 billion project to develop magnetically controlled radiotherapy equipment

South Korean medical device company Radexel announced on August 24 that it has been selected as the lead institution for a global flagship project, partnering with Asan Medical Center, the Korea Atomic Energy Research Institute (KAERI), and other organizations to develop next-generation radiotherapy equipment based on magnetic field control. The project is a national strategic R&D initiative jointly promoted by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, and the Ministry of Food and Drug Safety, with a total investment of KRW 35.2 billion, including KRW 27.95 billion in government funding, over a seven-year period. Under the plan, the Radexel consortium will develop a Magnetically Controlled Radiotherapy (MPRT) system. This technology controls secondary...

2026-08-24

Atom High-Tech Adds New Radiopharmaceutical Production Base in Changchun

The Jilin Provincial Medical Products Administration issued a public notice on August 21 stating that, in accordance with the Drug Administration Law of the People's Republic of China, the Regulations on the Administration of Radiopharmaceuticals, the Measures for the Supervision and Administration of Drug Production, and other relevant provisions, following on-site inspection and review approval, it intends to issue the Radiopharmaceutical Production License to Changchun Atom High-Tech Pharmaceutical Co., Ltd. The public notice period is 5 working days, subject to public supervision. The notice information shows that the registered address of Changchun Atom High-Tech Pharmaceutical Co., Ltd. is located at No. 770 Shengye Road, Beihu Science and Technology Development Zone, Changchun City, Jilin Province, and the proposed production address for the license is consistent with the registered address. The proposed production scope for this license is small-volume injections for in vivo radiopharmaceuticals, involving products such as Sodium Pertechnetate [99mTc] Injection, Technetium [99mTc] Methylenediphosphonate Injection, Technetium [99mTc] Methoxyisonitrile Injection, Technetium [99mTc] Pentetate Injection, Technetium [99mTc] Ethyl Cysteinate Dimer Injection, and Technetium [99mTc] Etifenin Injection.

2026-08-24

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

On August 22, the groundbreaking ceremony for the Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project was held in Hengyang, Hunan Province. Officials from Hengyang City and Zhuhui District, representatives from relevant colleges of the University of South China, investment institutions, and relevant personnel from New Radiopharmaceutical Medical attended the event. Cai Jiming, Chairman and President of New Radiopharmaceutical Medical, stated at the ceremony that the project's landing in Hengyang represents an important strategic layout for the company's nuclear medicine business. From contract signing to construction commencement, the project has received support from local governments, partners, and relevant organizations. The company will leverage this project as an opportunity to continue advancing the transformation of innovative achievements in the fields of medical isotopes and radiopharmaceuticals. Wang Jing, Deputy Mayor of Hengyang City, stated that Hengyang...

2026-08-22

CNNC Particle and Beijing Institute of Medical Device Testing Carry Out Joint Learning and Co-building Activity

On August 20, CNNC Particle and the Beijing Institute of Medical Device Testing carried out a joint learning and co-building activity. Representatives from both sides engaged in in-depth discussions on topics such as Party building leading business development, joint development of technical standards, and enhancement of inspection and testing capabilities. Wu Wei, Secretary of the Party Branch and Director of CNNC Particle, Wu Kechun, Deputy Secretary of the Party Committee of the Institute, and more than twenty Party member representatives from both sides participated in the event. At the beginning of the event, the CNNC Particle delegation visited the Institute's laboratories to gain first-hand understanding of its technical capabilities and research progress in inspection and testing. The Institute's advanced experimental platforms and technologies left a deep impression on the visitors. During the discussion session, Wu Kechun and Wu Wei delivered speeches respectively. Both sides...

2026-08-22

Cubresa Brain PET Scanner Receives FDA 510(k) Clearance, Integrates with Existing PET/MR Systems

Molecular imaging technology company Cubresa Inc. announced on August 20 that its Cubresa BrainPET™ scanner has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). According to the company, the Cubresa BrainPET™ is a positron emission tomography (PET) device specifically designed for brain imaging and can be integrated into existing Siemens Biograph mMR MR/PET systems. The device enables healthcare institutions to perform simultaneous PET/MR brain imaging on existing MRI infrastructure, capturing molecular and anatomical information without the need to purchase a separate whole-body hybrid imaging system. Cubresa founder and CEO James ...

2026-08-22

South Korea's Asan Medical Center Develops AI-Based Radiopharmaceutical Therapy Platform with U.S. Institutions

The research team at Asan Medical Center in Seoul announced on the 21st that it has recently been selected for the "2026 Korea-U.S. Innovative Outcomes R&D New Support Project" organized by the Ministry of Health and Welfare, and will collaborate with U.S. research institutions to develop an artificial intelligence-based radiopharmaceutical therapy platform aimed at exploring new treatment strategies for solid tumors that respond poorly to conventional therapies. The team is composed of professors including Myung Seung-jae from the Department of Gastroenterology, Oh Seung-jun from the Department of Nuclear Medicine, Ryu Chang-hoon from the Department of Oncology, Jung Byung-kwan from the Department of Pathology, and Son Byung-ho from the Department of Breast Surgery at Asan Medical Center. The project will combine Asan Medical Center's large-scale clinical and pathological data, Emory University's AI-based digital pathology analysis technology, and Case Western Reserve University and University Hospitals Cleveland Medical Center's pathological and clinical research capabilities.

2026-08-22